Drugs / HLX43
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06115642 | Nov 2023 → Jun 2026 overdue | metastatic malignant neoplasm | Shanghai Henlius Biotech | Enrolling by invitation | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07358585 | Jan 2026 → Jul 2027 expected | colon adenocarcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06848699 | Feb 2025 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07487519 | Apr 2026 → May 2027 expected | triple-negative breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07459738 | Apr → Dec 2026 expected | hormone receptor-positive breast cancer | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07269782 | Jan → Jul 2026 overdue | non-small cell lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT07253142 | Jan 2026 → Jun 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07301229 | Dec 2025 → Feb 2028 expected | pancreatic ductal adenocarcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07115485 | Sep 2025 → Aug 2027 expected | gastroesophageal adenocarcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT07106892 | Sep 2025 → Dec 2026 expected | colorectal cancer | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06907615 | Jun 2025 → Apr 2028 expected | non-small cell lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06857279 | Apr 2025 → Dec 2027 expected | head and neck carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06839066 | Apr 2025 → Nov 2026 expected | nasopharyngeal carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06742892 | Mar 2025 → Oct 2026 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06769152 | Feb 2025 → Dec 2026 expected | cervical cancer, ovarian cancer | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06769113 | Jan 2025 → Oct 2026 expected | esophageal cancer | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07459751 | May 2026 → Jan 2030 expected | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX43 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06907615 ↗ |
| Action | Inhibit | “HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.” NCT06742892 ↗ |
| Modality | Other / unclassified | “HLX43 (Anti-PD-L1 ADC)” NCT06115642 ↗ |
| Route | Intravenous | “administered with HLX43 at different doses via intravenous infusion” NCT06115642 ↗ |